ClinicalTrials.gg
CompletedNCT00303459Compass-2Updated Feb 4, 2025Results posted

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)

A Phase 4 interventional study of bosentan and placebo in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.

Enrollment
Largest of 18
334 · median 37
Started
2006
with 2 others
Phase 4
5 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
10 of 18
Actelion

Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one has the largest enrollment, is one of 3 that started in 2006, is one of 5 in phase 4, and was the 2nd registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing bosentan in Pulmonary Arterial Hypertension as a file.
02

Study summary

COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH already receiving sildenafil therapy. Patients must have been receiving doses of sildenafil equal to or greater than 20 mg t.i.d. for at least 12 weeks prior to being randomized.

The study continued until the predefined target number of morbidity/mortality events was reached.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • sildenafil
  • Combination Drug Therapy
  • bosentan
  • Pulmonary Hypertension
  • Pulmonary Arterial Hypertension
  • Multicenter Study
  • Antihypertensive Agents
  • Tracleer
  • endothelin receptor antagonist
  • Randomized Controlled Trial
  • Phosphodiesterase type 5 inhibitor (PDE5i)
  • Outcome Assessment
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to initiation of any study-mandated procedure
  2. Males or females >=12 years of age (except for countries where this age limit is contrary to specific regulatory requirements).

    • Women of must have a negative pretreatment pregnancy test and must use a reliable method of during study treatment and for at least 3 months after study treatment termination.

    ·Reliable methods of contraception are:

    O Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in combination with a spermicide.

    O Intrauterine devices. O Oral, transdermal, injectable or implantable contraceptives only in combination with a barrier method.

    • Hormone-based contraceptives alone, regardless of the route of administration, are not considered as reliable methods of contraception.
    • Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception.

      • Women not of childbearing potential are defined as (i.e., amenorrhea for at least 1 year), or documented surgically or naturally sterile.
  3. Patients with symptomatic PAH
  4. Patients with the following types of PAH belonging to WHO Group I:

    • Idiopathic (IPAH)
    • Familial (FPAH)
    • Associated with (APAH):

      i. Collagen vascular disease with normal left ventricular function ( (EF) > 50%) ii. Congenital systemic-to-pulmonary shunts at least 2 years post surgical repair iii. Drugs and toxins

  5. PAH diagnosed by right heart catheter showing:

    • Mean pulmonary arterial pressure (mPAP) >= 25 mm Hg AND
    • Pulmonary capillary wedge pressure (PCWP) =\< 15 mm Hg or left ventricular end diastolic pressure (LVEDP) =\< 15 mmHg If both PCWP and LVEDP are available then the LVEDP value is retained for inclusion.
  6. Treatment with a stable dose of sildenafil equal to or greater than 20 mg t.i.d. for at least 12 weeks prior to randomization (no sildenafil dosage adjustment should occur in this period) 7)150 m =\< 6-minute walk test (6MWT) =\< 480 m, documented by 2 tests with second 6MWT within 15% of first 6MWT distance or a third test required

Exclusion criteria

Exclusion Criteria :

  1. PAH belonging to WHO group II-V
  2. PAH associated with portal hypertension and infection
  3. PAH associated with thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders and splenectomy
  4. PAH associated with significant venous or capillary involvement (PCWP > 15 mmHg): pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis
  5. Persistent pulmonary hypertension of the newborn
  6. Significant valvular disease with valvular lesions to be excluded by echocardiogram within 2 years prior to randomization (i.e. patients with tricuspid or pulmonary insufficiency secondary to PAH can be included)
  7. Restrictive lung disease: total lung capacity (TLC) \< 60% of normal predicted value (see Appendix 3)
  8. Obstructive lung disease: forced expiratory volume/forced vital capacity (/FVC) \< 0.5
  9. Moderate to severe hepatic impairment, i.e., Class B or C
  10. Known HIV infection
  11. Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements or that may interfere with the safety or the evaluation of the study, such as chronic infection, chronic renal failure etc.
  12. Psychotic, addictive or other disorder limiting the ability to provide or to comply with study requirements
  13. Pregnancy or breast-feeding
  14. Condition that prevents compliance with the protocol or adherence to therapy
  15. Systolic blood pressure \< 85 mmHg
  16. Body weight \< 40 kg
  17. \<75% of the lower limit of the normal range
  18. (AST) and/or alanine aminotransferase (ALT) > 1.5 times the ranges
  19. Known or history of drug-related adverse events with bosentan (e.g. increase in liver function test results), or any of the of its formulation
  20. Receipt of an product other than sildenafil within 3 months before start of study treatment
  21. Treatment with endothelin receptor antagonists (ERAs), prostanoids or phosphodiesterase (PDE) 5 inhibitors other than sildenafil within 3 months prior to randomization
  22. Concomitant systemic treatment within 1 week prior to randomization with

    • calcineurin inhibitors (e.g., cyclosporine A and tacrolimus), sirolimus and everolimus
    • glibenclamide (glyburide)
    • both cytochrome P2C9 (CYP2C9) and cytochrome P3A4 () (e.g., fluconazole, amiodarone, voriconazole)
    • combination of drugs that inhibit CYP2C9 and CYP3A4
  23. Treatment with nitrates and alpha-blockers at time of randomization
  24. In the opinion of the investigator - patients in need for treatment with any prostanoid up to Visit 4
  25. Significant left ventricular dysfunction
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
334 participants (actual)

Study arms

  • Experimental
    A

    Bosentan

    Drug: bosentan

  • Placebo comparator
    B

    Placebo

    Drug: placebo

Interventions

  • bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.

  • Drugplacebo

    Matching bosentan placebo/b.i.d.

06

What researchers measure

Primary outcomes

  1. Time to First Confirmed Morbidity/Mortality Event up to the End of Study

    Kaplan-Meier estimate of percentage of participants without a morbidity/mortality event. A morbidity/mortality event is defined as the occurrence of a) death, b) hospitalization for worsening or complication of PAH or intravenous prostanoid initiation, c) atrial septostomy, d) lung transplantation, or e) worsening PAH, defined as "moderately" or "markedly" worsened PAH symptoms using a patient global self-assessment (PGSA) scale AND initiation of inhaled or subcutaneous prostanoids or the disease progression package (open-label bosentan). If a patient replied "no change" or "mildly worse" on the PGSA, a decrease in 6MWT of 20% versus last visit or 30% versus baseline is also required to confirm the event.

    Time frame: From baseline to end of study, approximately 86 months

Secondary outcomes

  1. Time to First Confirmed Death, Hospitalization for Worsening or Complication of PAH or Initiation of Intravenous Prostanoids, Atrial Septostomy, or Lung Transplantation

    Kaplan-Meier estimate of percentage of participants without an event of death, hospitalization (for worsening or complication of PAH or initiation of intravenous prostanoids), atrial septostomy or lung transplantation. Time to first confirmed death, hospitalization (for worsening or complication of PAH or initiation of intravenous prostanoids), atrial septostomy or lung transplantation from baseline to end of study was confirmed by an independent Clinical Endpoint Committee.

    Time frame: Baseline to end of study, approximately 86 months

  2. Change From Baseline to Week 16 in 6 Minute Walk Test (6MWT)

    The 6MWT is a non-encouraged test, which measures the distance covered over a 6 minute walk; the patient is instructed to walk as far as possible in a 30 m long flat corridor, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Areas were to be well ventilated with air temperature controlled between 20 °C and 23 °C (68 °F to 76 °F). The test was to be administered at the same time of day and by the same tester throughout the study. The tester measured the distance walked by non-encouraged patients during the timed 6 minute period.

    Time frame: From baseline to week 16

  3. Number of Participants With Improved, No Change, or Worsened World Health Organisation Functional Class From Baseline to Week 16

    Class I: no limitation of usual physical activity (PA) which does not increase dyspnea, fatigue, chest pain, or presyncope. Class II: mild limitation of PA. No discomfort at rest. Normal PA increases dyspnea, fatigue, chest pain, or presyncope. Class III: marked limitation of PA. No discomfort at rest. Less than ordinary activity increases dyspnea, fatigue, chest pain, or presyncope. Class IV: unable to perform any PA and who may have signs of right ventricular failure. Dyspnea and/or fatigue may be present at rest and symptoms are increased by almost any PA.

    Time frame: From baseline to Week 16

  4. Time to Death of All Causes From Baseline to End of Study

    Kaplan-Meier estimate of percentage of participants without a mortality event.Time to death due to any cause.

    Time frame: Baseline to End of Study, approximately 86 months

  5. Adjusted Percentage Ratio From Baseline in N-terminal Pro-B-type Natriuretic Peptide (NT-pro-BNP)

    Blood sampling for the measurement of NT-pro-BNP was performed and the plasma concentrations of NT-pro-BNP were determined by a certified centralized laboratory.

    Time frame: Baseline to Month 20

  6. Change From Baseline to Week 16 in Borg Dyspnea Index

    The Borg dyspnea index was evaluated immediately after the 6MWT to obtain a rating of dyspnea at the end of the exercise using a scale from 0 ('Nothing at all') to 10 ('Very, very severe - maximal').

    Time frame: Baseline to Week 16

  7. Change From Baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) Questionnaire Calculated Score

    The EQ-5D questionnaire is a patient-reported outcome consisting of a 5 dimensional descriptive system and a visual analog scale (VAS). The descriptive system asks respondents to describe their health status. Health is defined in 5 dimensions: (1) mobility, (2) self care, (3) usual activities, (4) pain or discomfort, and (5) anxiety or depression. Each dimension is divided into 3 levels, indicating (a) no problem, (b) some or moderate problems, or (c) extreme problems. Respondents record their problem(s) in each of the 5 dimensions. Combinations of these levels define a total of 243 health states. A health state defined by the descriptive system of EQ-5D can be described by a 5-digit number with full health is indicated by 11111 and poorest health state by 33333. The EQ-5D calculated score was derived by re-assigning local scores for answers to each question and combining these local scores into a global score with ranges from 0 (worst possible outcome) to 1 (best possible outcome).

    Time frame: From baseline to Week 16

  8. Change From Baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) Visual Analogue Scale Score

    The EQ-5D questionnaire is a patient-reported outcome consisting of a 5 dimensional descriptive system and a visual analog scale (VAS) together with brief demographic questions. EQ-5D VAS asks respondents to rate their perception of their overall health on a vertical visual analogue scale with 'best imaginable health state' set at 100 and 'worst imaginable health state' set at 0.

    Time frame: Baseline to Week 16

  9. Patient Global Self Assessment (PGSA) Status at Week 16

    The PGSA is a questionnaire that allows the patient to compare his/her PAH status in response to the question "How do you feel about your PAH today compared with your last visit?" asked by the investigator. Patients use a seven-point scale to respond: markedly better, moderately better, mildly better, no change, markedly worse, moderately worse, or mildly worse.

    Time frame: Week 16

07

Results

Posted Jan 26, 2015

Participant flow

First subject, first visit was17 May 2006 and last subject, last visit was 05 Dec 2013.

Participant flow — Overall Study
MilestoneBosentanPlacebo
Started159175
Completed7686
Not completed8389
Withdrew: Death3344
Withdrew: Withdrawal of consent3226
Withdrew: Lost to follow-up54
Withdrew: Administrative reason77
Withdrew: Decision by the investigator57
Withdrew: Lung transplantation11

Outcome measures

PrimaryTime to First Confirmed Morbidity/Mortality Event up to the End of Study

Kaplan-Meier estimate of percentage of participants without a morbidity/mortality event. A morbidity/mortality event is defined as the occurrence of a) death, b) hospitalization for worsening or complication of PAH or intravenous prostanoid initiation, c) atrial septostomy, d) lung transplantation, or e) worsening PAH, defined as "moderately" or "markedly" worsened PAH symptoms using a patient global self-assessment (PGSA) scale AND initiation of inhaled or subcutaneous prostanoids or the disease progression package (open-label bosentan). If a patient replied "no change" or "mildly worse" on the PGSA, a decrease in 6MWT of 20% versus last visit or 30% versus baseline is also required to confirm the event.

Time frame:
From baseline to end of study, approximately 86 months
Reported as:
Number · percentage of participants-Kaplan Meier
Time to First Confirmed Morbidity/Mortality Event up to the End of Study
percentage of participants-Kaplan MeierBosentanPlacebo
Kaplan-Meier estimate at Month 496.190.6
Kaplan-Meier estimate at Month 890.583.0
Kaplan-Meier estimate at Month 1282.774.0
Kaplan-Meier estimate at Month 1674.771.0
Kaplan-Meier estimate at Month 2071.866.1
Kaplan-Meier estimate at Month 2466.661.5
Kaplan-Meier estimate at Month 2865.855.0
Kaplan-Meier estimate at Month 3262.452.7
Kaplan-Meier estimate at Month 3457.548.8
Kaplan-Meier estimate at Month 4056.448.0
Kaplan-Meier estimate at Month 4450.646.2
Kaplan-Meier estimate at Month 4846.745.2
Kaplan-Meier estimate at Month 5245.145.2
Kaplan-Meier estimate at Month 5645.142.6
Kaplan-Meier estimate at Month 6045.139.7
Kaplan-Meier estimate at Month 6445.139.7
Kaplan-Meier estimate at Month 6840.139.7
Kaplan-Meier estimate at Month 7240.139.7
Kaplan-Meier estimate at Month 7640.136.1
Kaplan-Meier estimate at Month 8040.136.1
Kaplan-Meier estimate at Month 8440.136.1
Kaplan-Meier estimate at End of Study40.136.1
Statistical analysis
  • Bosentan vs Placebo · Log Rank · p = 0.2508 · Hazard ratio (hr): 0.831 · 97.31% CI 0.582 to 1.187
SecondaryTime to First Confirmed Death, Hospitalization for Worsening or Complication of PAH or Initiation of Intravenous Prostanoids, Atrial Septostomy, or Lung Transplantation

Kaplan-Meier estimate of percentage of participants without an event of death, hospitalization (for worsening or complication of PAH or initiation of intravenous prostanoids), atrial septostomy or lung transplantation. Time to first confirmed death, hospitalization (for worsening or complication of PAH or initiation of intravenous prostanoids), atrial septostomy or lung transplantation from baseline to end of study was confirmed by an independent Clinical Endpoint Committee.

Time frame:
Baseline to end of study, approximately 86 months
Reported as:
Number · percentage of participants-Kaplan Meier
Time to First Confirmed Death, Hospitalization for Worsening or Complication of PAH or Initiation of Intravenous Prostanoids, Atrial Septostomy, or Lung Transplantation
percentage of participants-Kaplan MeierBosentanPlacebo
Kaplan-Meier estimate at Month 497.495.3
Kaplan-Meier estimate at Month 894.691.8
Kaplan-Meier estimate at Month 1289.688.8
Kaplan-Meier estimate at Month 1685.386.9
Kaplan-Meier estimate at Month 2082.383.8
Kaplan-Meier estimate at Month 2476.979.8
Kaplan-Meier estimate at Month 2876.174.7
Kaplan-Meier estimate at Month 3275.273.1
Kaplan-Meier estimate at Month 3672.264.4
Kaplan-Meier estimate at Month 4072.261.9
Kaplan-Meier estimate at Month 4464.260.1
Kaplan-Meier estimate at Month 4860.358.1
Kaplan-Meier estimate at Month 5257.456.8
Kaplan-Meier estimate at Month 5653.852.7
Kaplan-Meier estimate at Month 6053.851.3
Kaplan-Meier estimate at Month 6453.851.3
Kaplan-Meier estimate at Month 6839.849.2
Kaplan-Meier estimate at Month 7239.849.2
Kaplan-Meier estimate at Month 7639.845.1
Kaplan-Meier estimate at Month 8039.845.1
Kaplan-Meier estimate at Month 8439.845.1
Kaplan-Meier estimate at End of Study39.845.1
Statistical analysis
  • Bosentan vs Placebo · Log Rank · p = 0.8385 · Hazard ratio (hr): 0.963 · 95% CI 0.673 to 1.380
SecondaryChange From Baseline to Week 16 in 6 Minute Walk Test (6MWT)

The 6MWT is a non-encouraged test, which measures the distance covered over a 6 minute walk; the patient is instructed to walk as far as possible in a 30 m long flat corridor, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Areas were to be well ventilated with air temperature controlled between 20 °C and 23 °C (68 °F to 76 °F). The test was to be administered at the same time of day and by the same tester throughout the study. The tester measured the distance walked by non-encouraged patients during the timed 6 minute period.

Time frame:
From baseline to week 16
Reported as:
Mean · m
Change From Baseline to Week 16 in 6 Minute Walk Test (6MWT)
mBosentanPlacebo
Baseline363 ± 78.5358 ± 73.1
Week 16370 ± 98.3343 ± 107.3
Change from baseline7.2 ± 66.01-14.6 ± 80.42
Statistical analysis
  • Bosentan vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0106 · Mean difference (net): 21.8 · 95% CI 5.9 to 37.8
SecondaryNumber of Participants With Improved, No Change, or Worsened World Health Organisation Functional Class From Baseline to Week 16

Class I: no limitation of usual physical activity (PA) which does not increase dyspnea, fatigue, chest pain, or presyncope. Class II: mild limitation of PA. No discomfort at rest. Normal PA increases dyspnea, fatigue, chest pain, or presyncope. Class III: marked limitation of PA. No discomfort at rest. Less than ordinary activity increases dyspnea, fatigue, chest pain, or presyncope. Class IV: unable to perform any PA and who may have signs of right ventricular failure. Dyspnea and/or fatigue may be present at rest and symptoms are increased by almost any PA.

Time frame:
From baseline to Week 16
Reported as:
Number · participants
Number of Participants With Improved, No Change, or Worsened World Health Organisation Functional Class From Baseline to Week 16
participantsBosentanPlacebo
Improved2528
No change121130
Worsened1317
Statistical analysis
  • Bosentan vs Placebo · Fisher Exact · p = 1.0000 · Relative risk of improvement: 0.98 · 95% CI 0.60 to 1.61
SecondaryTime to Death of All Causes From Baseline to End of Study

Kaplan-Meier estimate of percentage of participants without a mortality event.Time to death due to any cause.

Time frame:
Baseline to End of Study, approximately 86 months
Reported as:
Number · percentage of participants-Kaplan Meier
Time to Death of All Causes From Baseline to End of Study
percentage of participants-Kaplan MeierBosentanPlacebo
Kaplan-Meier estimate at Month 499.498.2
Kaplan-Meier estimate at Month 898.795.8
Kaplan-Meier estimate at Month 1296.594.0
Kaplan-Meier estimate at Month 1692.892.8
Kaplan-Meier estimate at Month 2090.689.5
Kaplan-Meier estimate at Month 2489.188.2
Kaplan-Meier estimate at Month 2885.885.9
Kaplan-Meier estimate at Month 3285.884.3
Kaplan-Meier estimate at Month 3685.878.5
Kaplan-Meier estimate at Month 4085.876.8
Kaplan-Meier estimate at Month 4481.474.9
Kaplan-Meier estimate at Month 4877.771.8
Kaplan-Meier estimate at Month 5275.070.5
Kaplan-Meier estimate at Month 5670.166.4
Kaplan-Meier estimate at Month 6067.864.9
Kaplan-Meier estimate at Month 6467.864.9
Kaplan-Meier estimate at Month 6867.864.9
Kaplan-Meier estimate at Month 7267.864.9
Kaplan-Meier estimate at Month 7667.860.3
Kaplan-Meier estimate at Month 8058.160.3
Kaplan-Meier estimate at Month 8458.160.3
Kaplan-Meier estimate at End of Study58.160.3
Statistical analysis
  • Bosentan vs Placebo · Log Rank · p = 0.4974 · Hazard ratio (hr): 0.855 · 95% CI 0.544 to 1.344
SecondaryAdjusted Percentage Ratio From Baseline in N-terminal Pro-B-type Natriuretic Peptide (NT-pro-BNP)

Blood sampling for the measurement of NT-pro-BNP was performed and the plasma concentrations of NT-pro-BNP were determined by a certified centralized laboratory.

Time frame:
Baseline to Month 20
Reported as:
Geometric mean · Adjusted percentage ratio from baseline
Adjusted Percentage Ratio From Baseline in N-terminal Pro-B-type Natriuretic Peptide (NT-pro-BNP)
Adjusted percentage ratio from baselineBosentanPlacebo
Month 1 to Baseline87.46 (77.12 to 99.18)110.02 (97.56 to 124.06)
Month 4 to Baseline92.65 (81.20 to 105.72)113.20 (99.61 to 128.65)
Month 8 to Baseline85.21 (72.58 to 100.05)122.87 (104.82 to 144.02)
Month 12 to Baseline84.48 (71.48 to 99.83)132.11 (111.95 to 155.89)
Month 16 to Baseline92.69 (75.75 to 113.42)129.92 (106.69 to 158.20)
Month 20 to Baseline98.36 (79.46 to 121.75)143.17 (115.86 to 176.91)
Treatment effect over 20 months92.54 (82.72 to 103.52)121.00 (108.42 to 135.05)
Statistical analysis
  • Bosentan vs Placebo · Repeated measures analysis · p = 0.0003 · Percentage change over placebo: -23.52 · 95% CI -33.69 to -11.79
SecondaryChange From Baseline to Week 16 in Borg Dyspnea Index

The Borg dyspnea index was evaluated immediately after the 6MWT to obtain a rating of dyspnea at the end of the exercise using a scale from 0 ('Nothing at all') to 10 ('Very, very severe - maximal').

Time frame:
Baseline to Week 16
Reported as:
Mean · units on a scale
Change From Baseline to Week 16 in Borg Dyspnea Index
units on a scaleBosentanPlacebo
Baseline3.5 ± 1.993.7 ± 2.18
Week 163.4 ± 2.123.6 ± 2.24
Change from baseline-0.09 ± 1.693-0.08 ± 2.035
Statistical analysis
  • Bosentan vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.9566 · Mean difference (net): -0.01 · 95% CI -0.42 to 0.39
SecondaryChange From Baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) Questionnaire Calculated Score

The EQ-5D questionnaire is a patient-reported outcome consisting of a 5 dimensional descriptive system and a visual analog scale (VAS). The descriptive system asks respondents to describe their health status. Health is defined in 5 dimensions: (1) mobility, (2) self care, (3) usual activities, (4) pain or discomfort, and (5) anxiety or depression. Each dimension is divided into 3 levels, indicating (a) no problem, (b) some or moderate problems, or (c) extreme problems. Respondents record their problem(s) in each of the 5 dimensions. Combinations of these levels define a total of 243 health states. A health state defined by the descriptive system of EQ-5D can be described by a 5-digit number with full health is indicated by 11111 and poorest health state by 33333. The EQ-5D calculated score was derived by re-assigning local scores for answers to each question and combining these local scores into a global score with ranges from 0 (worst possible outcome) to 1 (best possible outcome).

Time frame:
From baseline to Week 16
Reported as:
Mean · units on a scale
Change From Baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) Questionnaire Calculated Score
units on a scaleBosentanPlacebo
Baseline0.678 ± 0.21720.681 ± 0.2138
Week 160.662 ± 0.28070.645 ± 0.3062
Change from Baseline-0.0161 ± 0.25232-0.0361 ± 0.26671
Statistical analysis
  • Bosentan vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5571 · Mean difference (net): 0.020 · 95% CI -0.036 to 0.076
SecondaryChange From Baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) Visual Analogue Scale Score

The EQ-5D questionnaire is a patient-reported outcome consisting of a 5 dimensional descriptive system and a visual analog scale (VAS) together with brief demographic questions. EQ-5D VAS asks respondents to rate their perception of their overall health on a vertical visual analogue scale with 'best imaginable health state' set at 100 and 'worst imaginable health state' set at 0.

Time frame:
Baseline to Week 16
Reported as:
Mean · units on a scale
Change From Baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) Visual Analogue Scale Score
units on a scaleBosentanPlacebo
Baseline67 ± 17.464 ± 17.5
Week 1669 ± 19.966 ± 19.9
Change from Baseline2.1 ± 18.832.0 ± 17.01
Statistical analysis
  • Bosentan vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.4086 · Mean difference (net): 0.2 · 95% CI -3.7 to 4.0
SecondaryPatient Global Self Assessment (PGSA) Status at Week 16

The PGSA is a questionnaire that allows the patient to compare his/her PAH status in response to the question "How do you feel about your PAH today compared with your last visit?" asked by the investigator. Patients use a seven-point scale to respond: markedly better, moderately better, mildly better, no change, markedly worse, moderately worse, or mildly worse.

Time frame:
Week 16
Reported as:
Number · participants
Patient Global Self Assessment (PGSA) Status at Week 16
participantsBosentanPlacebo
Markedly better2413
Moderately better2330
Mildly better3236
No change5059
Mildly worse1615
Moderately worse35
Markedly worse24

Adverse events

Collected over Up to End of Study and up to 1 day after discontinuation of study treatment, approximately 86 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan—73/159 (45.9%)135/159 (84.9%)
Placebo—102/174 (58.6%)147/174 (84.5%)
Most frequent serious events
Showing 10 of 232
Most frequent serious events
EventBosentanPlacebo
PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders25/15928/174
PNEUMONIAInfections and infestations11/1596/174
DYSPNOEARespiratory, thoracic and mediastinal disorders5/1598/174
RIGHT VENTRICULAR FAILURECardiac disorders6/1598/174
CHEST PAINGeneral disorders5/1597/174
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders6/1593/174
BRONCHITISInfections and infestations6/1593/174
SYNCOPENervous system disorders3/1596/174
GASTROENTERITISInfections and infestations3/1595/174
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders4/1592/174
Most frequent other events
Showing 10 of 33
Most frequent other events
EventBosentanPlacebo
PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders15/15935/174
OEDEMA PERIPHERALGeneral disorders30/15926/174
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations21/15929/174
HEADACHENervous system disorders24/15924/174
COUGHRespiratory, thoracic and mediastinal disorders22/15921/174
DYSPNOEARespiratory, thoracic and mediastinal disorders21/15919/174
NAUSEAGastrointestinal disorders16/15922/174
BACK PAINMusculoskeletal and connective tissue disorders15/15922/174
DIARRHOEAGastrointestinal disorders19/15919/174
ARTHRALGIAMusculoskeletal and connective tissue disorders13/15920/174

Baseline characteristics

All randomized set

Age, Continuous
Age, Continuous(years)BosentanPlaceboTotal
Mean52.9 ± 15.4454.7 ± 15.7353.9 ± 15.60
Sex: Female, Male
Sex: Female, Male(Participants)BosentanPlaceboTotal
Female125128253
Male344781
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BosentanPlaceboTotal
Caucasian/White147149296
Black71219
Hispanic5611
Other088
Region of Enrollment
Region of Enrollment(participants)BosentanPlaceboTotal
Brazil363571
Czech Republic121527
Denmark347
Germany192241
Greece459
Portugal303
Saudi Arabia011
Slovakia437
Spain112
Sweden459
United Kingdom011
United States7383156
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • McLaughlin V, Channick RN, Ghofrani HA, Lemarie JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25. PubMed 26113687 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2006
First posted
Mar 17, 2006
Start
May 2006
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Jan 26, 2015
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00303459
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Mar 17, 2006
Start date
May 2006
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Jan 26, 2015
Last update
Feb 4, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion